Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-12

Clinical Trial Update: A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intranasal ketamine for obsessive-compulsive disorder was terminated; results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ketamine (intranasal) (ketamine)

Snippet

Sponsor: Mclean Hospital | Conditions: Obsessive-Compulsive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2017-05-12